Arbutus Biopharma CEO Discusses Lawsuits Over LNP Technology

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialArbutus Biopharma ( (ABUS) ) has issued an announcement. On December 11, 2025, Lindsay Androski, CEO of Arbutus Biopharma, presented at Roivant Sciences Ltd.’s Investor Day regarding ongoing lawsuits against Moderna, Pfizer, and BioNTech for using Arbutus’s patented LNP technology in COVID-19 vaccines. The litigation involves claims of patent infringement, with court hearings expected in 2026. Arbutus’s legal actions aim to secure compensation for the unauthorized use of their technology, which has been integral to the development of Moderna’s and Pfizer/BioNTech’s vaccines. The outcome of these lawsuits could significantly impact Arbutus’s financial position and its standing in the biotechnology sector. The most recent analyst rating on (ABUS) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page. Spark’s Take on ABUS Stock According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral. Arbutus Biopharma’s overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and negative cash flows. While technical analysis shows some stability, valuation remains unattractive due to negative earnings. Positive corporate events, including clinical trial progress and favorable legal outcomes, provide some support but are overshadowed by financial challenges. To see Spark’s full report on ABUS stock, click here. More about Arbutus Biopharma Arbutus Biopharma Corporation operates in the biotechnology industry, focusing on the development of nucleic acid medicines. The company is known for its lipid nanoparticle (LNP) technology, which is used in RNA delivery systems. Arbutus has a joint venture with Genevant Sciences to advance its LNP and ligand conjugate delivery technologies, while its primary focus remains on hepatitis B virus (HBV) therapeutics. Average Trading Volume: 1,018,664 Technical Sentiment Signal: Strong Buy Current Market Cap: $857.8M